Introduction
Among the rare group of natural killer-cell (NK-cell) malignancies, there are two which primarily involve the peripheral blood and bone marrow: aggressive NK-cell leukemia (ANKL) and chronic lymphoproliferative disorder of NK-cells (CLPDNK). ANKL is an EBV-associated tumor most prevalent among Asian young adults (median age of 42 years) [1] . It has a fulminant clinical course, presenting with fever and hepatosplenomegaly, complicated by multiple organ failure, coagulopathy and hemophagocytic syndrome, and frequently resulting in death within 2 months. In contrast, CLPDNK has no demonstrable association with EBV or racial predilection and tends to occur in older adults (median age of 60 years) [2] . Clinically, CLPDNK is similar to T-cell large granular lymphocytic leukemia with most patients incidentally found to have cytopenia(s) and/or a persistent increase in circulating mature NK-cells [3] . The clinical course is typically indolent.
Given the stark contrast in the clinical course and management of ANKL and CLPDNK, accurately discriminating between these two entities is very important. Morphologically, the tumor cells from both diseases can be similar and indistinguishable from their normal counterpart large granular lymphocytes. Immunophenotypically, although they are cell surface CD3 (sCD3)-negative and CD2-positive, the published data regarding these rare entities suggest that they can be very different in other surface antigen expression. ANKL is thought to usually exhibit a CD56+/CD16À/CD57À phenotype [1, [4] [5] [6] , whereas CLPDNK shows a CD56À/CD16+/CD57+ phenotype [7, 8] . Here, we report an unusual case of NK-cell neoplasm having an immunophenotype similar to that associated with ANKL but with clinical and laboratory features typical of the much more indolent CLPDNK.
Case Report
The patient is a 65-year-old Caucasian male with a 16-year history of leukopenia and neutropenia with his white blood count (WBC) varying from 1.8 9 10 9 /L to 3.5 9 10 9 /L and his absolute neutrophil count (ANC) ranging 0.5 9 10 9 /L to 0.7 9 10 9 /L. He was completely asymptomatic, denying fevers, night sweats, or unexplained weight loss and had no documented history of neutropenic infection. At the time of his follow-up, the WBC was 2.7 9 10 9 /L with neutrophils 0.6 9 10 9 /L and lymphocytes 2.1 9 10 9 /L, hemoglobin 9.7 g/dL and platelets 127 9 10 9 /L. Ultrasound revealed an enlarged spleen (16.2 9 15.8 9 9.0 cm) without focal masses. No hepatomegaly or lymphadenopathy was found. The patient had not received therapy for this condition.
Pathologic Findings
The peripheral blood smear showed an increase in granular lymphocytes with bland nuclei and abundant palestaining cytoplasm containing fine to coarse azurophilic granules (Fig. 1B) . No nuclear atypia, such as enlargement, folding, or open chromatin, was noted. Peripheral blood flow cytometric immunophenotyping revealed significantly increased NK-cells (84% of gated lymphoid events and 66% of total analyzed events) that were CD2-positive, sCD3-negative, and CD5-negative, with abnormally diminished CD7 expression (Fig. 1A) . They were doubly negative for CD4 and CD8 (Fig. 1A) . The neoplastic cells were CD56-positive, displayed aberrantly diminished CD16, and lacked CD57 expression (Fig. 1A) . Further, they exhibited aberrantly uniform expression of CD94 and NKG2A, and a complete absence of expression of the killer cell immunoglobulin-like receptors (KIRs), CD158a, CD158b, and CD158e (Fig. 1A) . Hematoxylin and eosin-stained bone marrow biopsy showed a slight increase in interstitial lymphocytes (10-15% of cellularity) which by immunohistochemical studies were positive for CD3 (Fig. 1C) , granzyme B (Fig. 1D ) and TIA-1 (Fig. 1E ) and distributed in an interstitial as well as an intrasinusoidal pattern. In situ hybridization for EBV-encoded RNA (EBER) was negative and no clonal T-cell receptor gene rearrangements were detected by peripheral blood PCR studies. Cytogenetic studies revealed a normal male karyotype. In conjunction with clinical and pathological features, a diagnosis of "chronic lymphoproliferative disorder of NK cells" was rendered.
Discussion
The diagnosis of NK-cell leukemia is challenging for practicing pathologists because NK-cells lack a singular lineage defining antigen and are phenotypically similar to normal cytotoxic T-cells. For this reason, flow cytometric immunophenotyping is a primary laboratory tool for this purpose as it allows for the accurate identification of NKcells through combined assessment of antigens which are expressed by these cells such as CD2, CD7, CD16, and CD56, and antigens which are not expressed such as sCD3 and CD5. Furthermore, flow cytometry is also critically important for determining if the NK-cells are leukemic as making this determination rests solely on the detection of phenotypic aberrancy, as NK-cells, by definition, do not harbor uniquely rearranged antigen receptor genes to serve as a marker of clonal cellular expansion. The power of flow cytometry to detect and define NKcell phenotypic aberrancy has been greatly enhanced by the analysis of a group of NK-cell receptors including the KIR antigens CD158a, CD158b, and CD158e and also CD94/NKG2A heterodimers. These utility of these assays in identifying NK-cell leukemia has been most extensively studied in CLPDNK, where distinction of the leukemic NK-cells from normal NK-cell expansion is problematic due to the indolent nature of the condition. The published literature indicates that CLPDNK is typically brightly CD16-positive and CD57-positive (majority of cases), a subset having diminished or absent expression of CD56 [7] [8] [9] [10] . Abnormal uniform expression of a single KIR antigen, or abnormal absence of all KIR antigens, is seen in essentially all CLPDNK cases, and over one-half have abnormally uniform expression of CD94/NKG2A heterodimers [8, 10, 11] . Although these features are included in the WHO description of this provisional entity [12] , there are few large studies with complete clinical phenotyping and therefore these observations are based on collectively, fewer than 200 published cases.
Aggressive NK-cell leukemia is believed to have a phenotype distinct from that of CLPDNK. Much of the previous data regarding the phenotype of ANKL are generated from immunohistochemical studies, which limits their utility in regards to comparison to flow cytometry [6] . Recently, comprehensive flow cytometric immunophenotyping studies for ANKL from a Japanese group of 22 cases [1] , European group of 12 cases [4] , and a Chinese group of 29 cases [5] revealed that all cases have bright CD56 expression and lack CD57 expression. The vast majority of cases do not express CD16 or CD8 [4] [5] [6] , although some cases are CD16 positive [1] . However, our understanding of the disease phenotype is only based on a very small number of published cases. Although CLDPNK and ANKL have dramatically different clinical manifestations, the paucity of data regarding the specificity of the disease phenotypes can be problematic from the laboratory standpoint, particularly in the reference laboratory setting where there may be little or no clinical information provided. Because of this, it can be difficult to render a definitive pathologic diagnosis which guides the clinical management of the case. This is illustrated by this case presented here as the leukemic NK-cells had a CD56+/CD16À/CD57À, immunophenotype putatively of ANKL. Nevertheless, the clinical, morphologic and pathologenetic (EBV status) were those of CLPDNK (Table 1) , treatment of which depends on the severity of clinical symptoms and cytopenias. ANKL is highly associated with EBV infection, and thus absence of EBV should make one question the diagnosis. Given the indolent behavior and negative EBV infection, the diagnosis of chronic lymphoproliferative disorder of NK-cells was favored, despite the "aggressive" immunophenotype. Whether this will eventually evolve into an aggressive form is uncertain and long clinical follow-up is warranted. Immunophenotyping plays a key role in distinguishing ANKL from CLDPNK, however, it could not be used as sole criteria and clinical/laboratory findings are equally important.
